Neurological disorders are the primary cause of physical and cognitive disabilities worldwide, currently impacting about 15% of the global population. With the expansion of the aging population, the burden of such conditions is projected to at least double over the next 20 years. Neurodegenerative diseases involve the gradual loss of neurons and include well-known disorders such Alzheimer’s, Huntington’s, and Parkinson’s, as well as rarer conditions such Progressive Supranuclear Palsy (PSP).

Despite their diverse clinical manifestations, neurodegenerative diseases share common features and mechanisms. One such feature is the aggregation of tau protein which has been recognized as a potential unifying factor in multiple diseases. The Neurodegeneration and Cognition Lab aim to investigate the pathophysiological mechanisms underlying tauopathies and provide a cost-effective preclinical model system for evaluating personalized, response-based treatments in neurodegenerative diseases related to tauopathies.